Role of DNA methylation in the regulation of the RANKL-OPG system in human bone

Epigenetics

Volumn 7, Issue 1, 2012, Pages 83-91

  Delgado Calle, Jesús ^a   Sañudo, Carolina ^a   Fernández, Agustín F ^b   García Renedo, Raúl ^c   Fraga, Mario F ^b,d   Riancho, José A ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

Bone remodeling; DNA methylation; Osteoblasts; Osteoporosis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ARTICLE; BONE TISSUE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FRAGILITY FRACTURE; GENE REPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HIP FRACTURE; HIP OSTEOARTHRITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; OSTEOCLASTOGENESIS; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PYROSEQUENCING; TRANSCRIPTION INITIATION;

EID: 84870279539     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.7.1.18753     Document Type: Article

References (43)

1. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008; 473:139-46; PMID:18395508; http://dx.doi.org/10.1016/j.abb.2008.03.018.
2. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95:3597-602; PMID:9520411; http://dx.doi.org/10.1073/pnas.95.7.3597.
3. Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlondorff J, et al. Evidence for a role of a tumor necrosis factoralpha (TNFalpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999; 274:13613-8; PMID:10224132; http://dx.doi.org/10.1074/jbc.274.19.13613.
4. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-19; PMID:9108485; http://dx.doi.org/10.1016/S0092-8674(00)80209-3.
5. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397:315-23; PMID:9950424; http://dx.doi.org/10.1038/16852.
6. Aoki S, Honma M, Kariya Y, Nakamichi Y, Ninomiya T, Takahashi N, et al. Function of OPG as a traffic regulator for RANKL is crucial for controlled osteoclastogenesis. J Bone Miner Res 2010; 25:1907-21; PMID:20560139; http://dx.doi.org/10.1002/jbmr.89.
7. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93:2149-57; PMID:18381571; http://dx.doi.org/10.1210/jc.2007-814.
8. Genant HK, Engelke K, Hanley DA, Brown JP, Omizo M, Bone HG, et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 2010; 47:131-9; PMID:20399288; http://dx.doi.org/10.1016/j.bone.2010.04.594.
9. Silvestrini G, Ballanti P, Patacchioli F, Leopizzi M, Gualtieri N, Monnazzi P, et al. Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. J Mol Histol 2005; 36:59-67; PMID:15704000; http://dx.doi.org/10.1007/s10735-004-3839-1.
10. Ikeda T, Utsuyama M, Hirokawa K. Expression profiles of receptor activator of nuclear factorkappaB ligand, receptor activator of nuclear factorkappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. J Bone Miner Res 2001; 16:1416-25; PMID:11499864; http://dx.doi.org/10.1359/jbmr.2001.16.8.1416.
11. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med 2011; 17:1235-41; PMID:21909103; http://dx.doi.org/10.1038/nm.2448.
12. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011; 17:1231-4; PMID:21909105; http://dx.doi.org/10.1038/nm.2452.
13. Fu Q, Jilka RL, Manolagas SC, O'Brien CA. Parathyroid hormone stimulates receptor activator of NFkappaB ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem 2002; 277:48868-75; PMID:12364326; http://dx.doi.org/10.1074/jbc.M208494200.
14. Kim S, Yamazaki M, Zella LA, Shevde NK, Pike JW. Activation of receptor activator of NFkappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol Cell Biol 2006; 26:6469-86; PMID:16914732; http://dx.doi.org/10.1128/MCB.00353-06.
15. O'Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NFkappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 1999; 274:19301-8; PMID:10383440; http://dx.doi.org/10.1074/jbc.274.27.19301.
16. Kieslinger M, Folberth S, Dobreva G, Dorn T, Croci L, Erben R, et al. EBF2 regulates osteoblast-dependent differentiation of osteoclasts. Dev Cell 2005; 9:757-67; PMID:16326388; http://dx.doi.org/10.1016/j.devcel.2005.10.009.
17. Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005; 8:751-64; PMID:15866165; http://dx.doi.org/10.1016/j.devcel.2005.02.017.
18. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006; 31:89-97; PMID:16403636; http://dx.doi.org/10.1016/j.tibs.2005.12.008.
19. Kitazawa R, Kitazawa S. Methylation status of a single CpG locus 3 bases upstream of TATA-box of receptor activator of nuclear factorkappaB ligand (RANKL) gene promoter modulates cell- and tissue-specific RANKL expression and osteoclastogenesis. Mol Endocrinol 2007; 21:148-58; PMID:17008384; http://dx.doi.org/10.1210/me.2006-0205.
20. Lu TY, Kao CF, Lin CT, Huang DY, Chiu CY, Huang YS, et al. DNA methylation and histone modification regulate silencing of OPG during tumor progression. J Cell Biochem 2009; 108:315-25; PMID:19565568; http://dx.doi.org/10.1002/jcb.22256.
21. Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 2010; 19:698-711; PMID:21074720; http://dx.doi.org/10.1016/j.devcel.2010.10.005.
22. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-59; PMID:18337604; http://dx.doi.org/10.1056/NEJMra072067.
23. Ulaner GA, Vu TH, Li T, Hu JF, Yao XM, Yang Y, et al. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet 2003; 12:535-49; PMID:12588801; http://dx.doi.org/10.1093/hmg/ddg034.
24. Suzuki J, Ikeda T, Kuroyama H, Seki S, Kasai M, Utsuyama M, et al. Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells. Biochem Biophys Res Commun 2004; 314:1021-7; PMID:14751235; http://dx.doi.org/10.1016/j.bbrc.2003.12.191.
25. Carda C, Silvestrini G, Gomez de Ferraris ME, Peydro A, Bonucci E. Osteoprotegerin (OPG) and RANKL expression and distribution in developing human craniomandibular joint. Tissue Cell 2005; 37:247-55; PMID:15899507; http://dx.doi.org/10.1016/j.tice.2005.03.002.
26. Patra SK, Patra A, Rizzi F, Ghosh TC, Bettuzzi S. Demethylation of (Cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer development. Cancer Metastasis Rev 2008; 27:315-34; PMID:18246412; http://dx.doi.org/10.1007/s10555-008-9118-y.
27. Dequeker J, Aerssens J, Luyten FP. Osteoarthritis and osteoporosis: clinical and research evidence of inverse relationship. Aging Clin Exp Res 2003; 15:426-39; PMID:14703009.
28. Neilson M, White A, Malik U, Morrison E, McGill PE, McDonald SW. Changes in bone architecture in the femoral head and neck in osteoarthritis. Clin Anat 2004; 17:378-91; PMID:15176035; http://dx.doi.org/10.1002/ca.10177.
29. Jordan GR, Loveridge N, Bell KL, Power J, Dickson GR, Vedi S, et al. Increased femoral neck cancellous bone and connectivity in coxarthrosis (hip osteoarthritis). Bone 2003; 32:86-95; PMID:12584040; http://dx.doi.org/10.1016/S8756-3282(02)00920-1.
30. Logar DB, Komadina R, Prezelj J, Ostanek B, Trost Z, Marc J. Expression of bone resorption genes in osteoarthritis and in osteoporosis. J Bone Miner Metab 2007; 25:219-25; PMID:17593491; http://dx.doi.org/10.1007/s00774-007-0753-0.
31. D'Amelio P, Roato I, D'Amico L, Veneziano L, Suman E, Sassi F, et al. Bone and bone marrow pro-osteoclastogenic cytokines are upregulated in osteoporosis fragility fractures. Osteoporos Int 2011; 22:2869-77; PMID:21116815; http://dx.doi.org/10.1007/s00198-010-1496-7.
32. Fraga MF, Esteller M. Epigenetics and aging: the targets and the marks. Trends Genet 2007; 23:413-8; PMID:17559965; http://dx.doi.org/10.1016/j.tig.2007.05.008.
33. Fraga MF. Genetic and epigenetic regulation of aging. Curr Opin Immunol 2009; 21:446-53; PMID:19500963; http://dx.doi.org/10.1016/j.coi.2009.04.003.
34. Penolazzi L, Lambertini E, Giordano S, Sollazzo V, Traina G, del Senno L, et al. Methylation analysis of the promoter F of estrogen receptor alpha gene: effects on the level of transcription on human osteoblastic cells. J Steroid Biochem Mol Biol 2004; 91:1-9; PMID:15261302; http://dx.doi.org/10.1016/j.jsbmb.2004.02.005.
35. Kang MI, Kim HS, Jung YC, Kim YH, Hong SJ, Kim MK, et al. Transitional CpG methylation between promoters and retroelements of tissue-specific genes during human mesenchymal cell differentiation. J Cell Biochem 2007; 102:224-39; PMID:17352407; http://dx.doi.org/10.1002/jcb.21291.
36. Fu Q, Manolagas SC, O'Brien CA. Parathyroid hormone controls receptor activator of NFkappaB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol 2006; 26:6453-68; PMID:16914731; http://dx.doi.org/10.1128/MCB.00356-06.
37. McAllister RM, Gardner MB, Greene AE, Bradt C, Nichols WW, Landing BH. Cultivation in vitro of cells derived from a human osteosarcoma. Cancer 1971; 27:397-402; PMID:5100401; http://dx.doi.org/10.1002/1097-0142(197102)27:2397::AID-CNCR28202702243.0.CO;2-X.
38. Heremans H, Billiau A, Cassiman JJ, Mulier JC, de Somer P. In vitro cultivation of human tumor tissues. II. Morphological and virological characterization of three cell lines. Oncology 1978; 35:246-52; PMID:218153; http://dx.doi.org/10.1159/000225298.
39. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36:59-74; PMID:886304; http://dx.doi.org/10.1099/0022-1317-36-1-59.
40. Jonsson KB, Frost A, Nilsson O, Ljunghall S, Ljunggren O. Three isolation techniques for primary culture of human osteoblast-like cells: a comparison. Acta Orthop Scand 1999; 70:365-73; PMID:10569267; http://dx.doi.org/10.3109/17453679908997826.
41. Sasaki M, Anast J, Bassett W, Kawakami T, Sakuragi N, Dahiya R. Bisulfite conversion-specific and methylation-specific PCR: a sensitive technique for accurate evaluation of CpG methylation. Biochem Biophys Res Commun 2003; 309:305-9; PMID:12951050; http://dx.doi.org/10.1016/j.bbrc.2003.08.005.
42. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc 2007; 2:2265-75; PMID:17853883; http://dx.doi.org/10.1038/nprot.2007.314.
43. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003; 35:146-50; PMID:12866414.